High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors

High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors

Proteasome inhibitors (PIs) are approved backbone treatments in multiple myeloma. More recently, inhibition of proteasome activity with the PI bortezomib has been clinically evaluated as a novel treatment strategy in pediatric acute lymphoblastic leukemia (ALL). However, we lack a marker that could...

Full description

Bibliographic Details
Main Authors: Lenka Besse, Andrej Besse, Marianne Kraus, Elmer Maurits, Herman S. Overkleeft, Beat Bornhauser, Jean-Pierre Bourquin, Christoph Driessen
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Cells
Subjects:
BCP-ALL
T-ALL
pediatric leukemia
immunoproteasome
proteasome inhibitors
LU015i
Online Access:https://www.mdpi.com/2073-4409/10/11/2853

Internet

https://www.mdpi.com/2073-4409/10/11/2853

Similar Items